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Abstract The aim of the present study was to assess the
origin of the substantia nigra hyperechogenicity in Par-
kinson disease patients. The cause of hyperechogenicity
was tested on an animal model. Fresh porcine brains were
injected consecutively with ferritin, apoferritin and water.
Then, glioma samples were inserted into animal model.
The echogenicity of the region of interest was assessed
before and after experimental procedures. We observed the
same echogenicity of porcine brain before and after
injections of iron-loaded ferritin, apoferritin and water.
Increased echogenicity of glioma samples compared to
surrounding porcine brain tissue could be clearly seen. We
postulate that the relative gliosis might be, at least partially,
responsible for the increased echogenicity of the substantia
nigra in Parkinson disease patients. Keeping in mind all
limitations and inaccuracies of animal model used, it seems
that hyperechogenicity of substantia nigra is caused rather
by structural changes within the brain tissue than by
increased iron concentration.
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Introduction
Differential diagnosis of Parkinson’s disease (PD) and
atypical parkinsonian syndromes is based mainly on clin-
ical examination (Hughes et al. 2002). Transcranial
sonography (TCS) could serve as easily accessible, quick
and safe diagnostic tool for movement disorders neurolo-
gist. Recent studies indicate that midbrain abnormalities
determined by TCS might be useful ﬁndings in uncertain
cases of parkinsonism (Becker et al. 1995; Berg et al.
1999a; Walter et al. 2003). Becker et al. postulated that the
relative increase of glial cells concentration and micro-
structural changes in the SN may result in increased tissue
echogenicity. Further studies concentrated on the role of
iron in the hyperechogenicity of SN (Berg et al. 1999b,
2002; Zecca et al. 2005). Berg et al. injected rat brains with
ionic iron, ferritin, 6-OHDA together with desferriox-
amine, zinc and buffer into the SN. A dose-dependent
increase of SN echogenicity was observed in the case of
ionic iron injection only. In another study, Zecca et al.
(2005) scanned post-mortem human brains at different
ages. The correlation was observed between SN echoge-
nicity and the concentration of iron measured by atomic
absorption spectroscopy as well as between SN hyperech-
ogenicity and H- and L-ferritins. The exact role of iron in
parkinsonian neurodegenerative process needs to be elu-
cidated. Accurate quantiﬁcation of iron levels in control
and PD brains (Wypijewska et al. 2010) shows that total
iron level remains unchanged and only labile iron level
increases. The concentration of labile iron is almost 2,000
times smaller than the concentration of total iron. In most
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microglia in substantia nigra hyperechogenicity was
emphasized again. The aim of this study was to assess the
inﬂuence of iron-loaded ferritin and glial tissue on echog-
enicity of the brain structures.
Methods
The study does not involve intervention for research pur-
poses or identiﬁable patient data.
Ultrasound imagining technique
Experiment was performed on Esaote MyLab 70XVision
ultrasound scanner equipped with 13–4 MHz Linear Array
probe working in B mode.
Animal model
The cause of hyperechogenicity was tested on an animal
model (Fig. 1). Fresh, i.e. max 8 h after animal death,
porcine brains were used. No method of tissue ﬁxation was
applied for the experiment. To obtain the homogeneous
structure, 3–4 brains were tightly put into the plastic holder
for each measurement. Brain tissue was consecutively
covered with skin and 5 mm layer of fat. Skin and fat
absorb ultrasounds similarly to skull. Special attention was
paid to remove all air bubbles, so free spaces were ﬁlled
with USG gel. In this study we did not aim to identify
particular brain structures. We used porcine brains as a
medium similar to human brain tissue for experimental
procedures. The experimental model we used was maxi-
mally simpliﬁed and, simultaneously, designed to mimic
conditions similar to those in real patients. It is not possible
to localize SN or any other particular anatomical structure
in such conditions. In spite of that, as described further in
the study, we were able to assess repeatable conditions and
well established localization for experimental procedures.
Ferritin (Sigma Aldrich horse spleen ferritin) of about
1c m
3 volume, containing 4,000 ± 200 lg/g of iron (the
concentration of iron was assessed by us with atomic
absorption), apoferritin (ferritin void of iron, Sigma
Aldrich horse spleen ferritin) also of about 1 cm
3 volume,
containing 4.0 ± 0.4 lg/g of iron and 1 cm
3 volume water
were injected, respectively, into our models and ultrasound
examination was performed for each injection separately.
Injection depth was 1.5–2 cm. In the next experiment,
samples of glial tissue obtained from human glioma
(approx. 0.2 cm
3 samples of astrocytoma GII and glioblas-
toma multiforme GIV, stored at -70, without tissue ﬁxa-
tion procedures before the experiment) after neurosurgical
operation were inserted into porcine brain and USG was
performed.
Region of interest was always marked either with the top
of injection needle in case of injections or with metal grid
for experiment with glial tissue. The localization of the
injection needle seen as the regular linear structure pro-
ducing intensive echo could be unequivocally determined.
Therefore, we were able to assess repeatable conditions for
experimental infusions. In the ﬁrst stage of the experiment,
the change of tissue echogenicity after ferritin, apoferritin
and water infusion was assessed. The echogenicity shift at
the site of the injection needle tip was visually evaluated
at the time and directly after the infusion. Then the pictures
of the ROI were also assessed by the same experienced
sonographist, to obtain better reliability. The TCS with
glioma tissue insertions was performed as next part of our
experiment with the use of the same porcine brain model.
Fig. 1 Animal model scheme and its photographic registration.
Injection needle can be seen on the right. Skin and fat on top—ﬁrst
bright layer
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123For better localization, tumour samples were inserted in the
centre of the metal grid and then tightly covered with brain
tissue as well as fat and skin layer. The ultrasound exam-
ination was performed before and after glioma insertion.
Photographic registration was also made and the images
were carefully assessed by experienced sonographist.
Quantiﬁcation of echogenicity
The change of tissue echogenicity after injections and glial
tissue insertions was assessed qualitatively by experienced
physician during model examinations.
Results
As seen in Fig. 1, all layers of animal model (i.e. fat plus
skin layer, porcine brain tissue, plastic holder wall) were
clearly depicted. Figure 2a, b, c shows the same echoge-
nicity of porcine brain before and after injections of iron-
loaded ferritin (a), apoferritin (b) and water (c). We were
unable to notice any change in tissue echogenicity except
subtle transient distortions caused by liquid ﬂow, which
were the same as typical for any liquid infusion. No stable
change was observed.
On the other hand, in the second part of our experiment
a marked hyperechogenicity in the area of glioma sample
insertion was noticed (Fig. 2d). There was no signiﬁcant
difference between GII and GIV samples.
Discussion
By deﬁnition, tissue echogenicity describes its ability to
create echo during ultrasound examination. In our study,
we were focused only on brightness change caused by
different factors. In clinical trials assessing substantia nigra
and other basal ganglia echogenicity in parkinsonian
patients, the area of hyperechogenic region is taken into
consideration. There is no accepted and standardized
method of tissue echogenicity assessment. Our experiment
has shown that ferritin overloaded with iron is not able to
cause brain tissue hyperechogenicity. It is important to note
that the concentration of iron in the ferritin injected in our
experiment was even higher than that in human substantia
nigra. Observed effect was similar to those of apoferritin or
water injection. There was no visible change in tissue
echogenicity in the region of interest. Should the hyper-
echogenicity of the SN in PD patients depend on iron
overload, injections of iron-loaded ferritin would have to
produce such an effect. Having in mind the dense structure
of the experimental model, physical rules of liquid diffu-
sion and the fact, that photographic registration was
performed immediately after infusions, it appears to be
improbable, that the infused liquids could leave the region
of interest and penetrate the surrounding tissue at the time
of experiment.
Our ﬁndings are, at least partially, in contradiction to
ﬁndings of Berg et al. (1999b). In our study, we did not use
living brains at any stage of the experiment. The mea-
surements were obtained immediately after experimental
injections, so, most probably, we were able to observe the
effect of injected substances ‘‘in situ’’ and in real time
before any biochemical interactions between injected
substances and surrounding tissue occurred. In the study by
Berg et al., experimental solutions were injected into the
SN of the living rat brain. Animals were killed 1 week after
stereotactic injection. Ultrasound examination and bio-
chemical analysis were performed post-mortem. Echoge-
nicity of the injected SN increased with the concentration
of iron injected. At 1.5 lg not only SN but also adjacent
brain structures were hyperechogenic. At 7.5 lg the ech-
ogenicity of the whole brain hemisphere increased. In our
opinion, this massive increase of ionic iron in SN and its
consequence is far from conditions met in SN of parkin-
sonian patients. Obviously, such a massive metal solution
injection would change tissue echogenicity. One has to
underline that after zinc injection, hyperechogenicity of the
whole hemisphere was also seen. Undoubtfully metal
injection changed tissue echogenicity. We do not know,
however, about the exact cause of this hyperechogenicity
(no histopathological data available). The question remains
what was going on within the injected hemisphere during
the week between injection and further experimental pro-
cedures. Iron injection might have caused inﬂammatory
glial response which might account for tissue hyperech-
ogenicity. This subject needs further research. Having this
in mind our own ﬁndings and ﬁndings of Berg et al. might
be only partially (if at all) conﬂicting.
One has to bear in mind that SN hyperechogenicity is
not pathognomonic for PD. About 10–15% of MSA and
PSP patients are characterized by the same ultrasound
feature. There is also a relatively high percentage (upto
80%) of patients with Lewy bodies dementia and cortico-
basal syndrome having hyperechogenicity of the SN
(Walter et al. 2006). The role of iron metabolism disequi-
librium in these particular neurodegenerative diseases
remains unclear, whereas neuronal loss and reactive gliosis
are obvious. One should mention that in physiological
conditions there are, except for the SN, other iron-rich
structures in the brain such as globus pallidus (GP) and red
nucleus (RN). These are non-detectable (GP) or variably
detectable (RN) by TCS. On the contrary, increased ech-
ogenicity of glioma samples compared to surrounding
brain tissue could be clearly seen. There was no signiﬁcant
difference between GII and GIV samples. It is obvious that
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123Fig. 2 a Left plain animal
model. Right same model after
ferritin injection. Injection
needle can be seen. b Left plain
animal model. Right same
model after apoferritin injection
on the right. Injection needle
can be seen. c Left plain animal
model. Right same model after
water injection. d Left plain
animal model. Right same
model with glioma inserted.
Needle (see interference
pattern) marked tissue insertion.
Hyperechogenicity compared to
plain model can be clearly seen
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123glioma samples cannot be treated as the equivalent of
microglial cells that gradually replace neurons in Parkin-
son’s disease. The exact structure, number and concentra-
tion of cells are different. Keeping in mind these
limitations, one has to pay attention to striking sensibility
of TCS in depicting brain tissue structure changes, espe-
cially connected with glial cells. TCS has been used for
many years as an useful diagnostic tool in neuro-oncology.
This method is especially useful in post-operative follow-
up of patients with high-grade gliomas being, in experi-
enced hands, one of the most sensitive techniques in
identiﬁcation of residual tumour (Becker et al. 1999). GII
and GIV glioma samples, we have used for the experiment,
were clearly visible. Applying this ﬁnding to Parkinson’s
disease there is a neuroinﬂammatory glial response present
in parkinsonian brains from the very beginning of neuro-
degenerative process. The relative number and activity of
glial cells appear to be stable during disease progression
(Ouchi et al. 2005), which corresponds well to the stable
area of SN hyperechogenicity observed in 5-years follow-
up (Berg et al. 2005). We hypothesize that gliosis is, at the
present level of knowledge, the simplest and most satis-
factory biological explanation of SN hyperechogenicity in
neurodegenerative diseases. The role of other considerable
factors such as changes in protein conformation or alfa-
synuclein aggregation remains to be elucidated.
To support our hypothesis the physics of ultrasound
examination could be taken into account. Ultrasound echo
is created due to reﬂection and scattering phenomena. As
reﬂection occurs only on boundaries, it is scattering that
actually produces tissue echogenicity. Magnitude of scat-
tering produced echogenicity is proportional to the number
of objects that actually interacts with ultrasound wave.
Therefore, the ratio between the object size and the ultra-
sound wave length is the most important factor. As proteins
and iron nanoparticles are much smaller than ultrasound
wave length, other factors like the change in cell properties
or arrangement seem to be much more signiﬁcant. Keeping
in mind all limitations and inaccuracies of animal model
used, it seems to be more probable that hyperechogenicity
of SN is caused rather by structural changes within the
brain tissue than by an increase of iron concentration.
Although our comparative studies are informative, still
more experiments are needed to elucidate hyperechoge-
nicity of SN in PD phenomena, particularly role of iron.
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